Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aboualkheir Alzaim

Internal Medicine Weymouth, MA Medical Doctor

NPI 1073595260 CMS profile 275224

540 Main St, Weymouth, MA 02192

Open in the dashboard

General payments

$3,517

171 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aboualkheir Alzaim of Weymouth, MA is reported in the CMS Open Payments database as having received $3,517 across 171 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $626 20
2024 General $542 19
2023 General $262 10
2022 General $427 22
2021 General $827 48
2020 General $519 33
2019 General $315 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aboualkheir Alzaim
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Aboualkheir Alzaim were reported at $626. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Aboualkheir Alzaim Internal Medicine median Middle half National median
2019 $315 $159 $48–$570 $163
2020 $519 $119 $33–$402 $114
2021 $827 $135 $37–$521 $132
2022 $427 $141 $42–$496 $149
2023 $262 $149 $45–$519 $160
2024 $542 $154 $47–$537 $164
2025 $626 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,727 71 payments
  2. Pfizer Inc. $704 45 payments
  3. Lilly USA, LLC $220 10 payments
  4. GlaxoSmithKline, LLC. $189 10 payments
  5. Novartis Pharmaceuticals Corporation $173 8 payments
  6. AbbVie, Inc. $141 9 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $95 5 payments
  8. Almatica Pharma LLC $46 2 payments
  9. Genentech USA, Inc. $36 2 payments
  10. Insmed, Inc. $33 1 payment
  11. Other $152 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,517 171 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $955 35 payments
  2. AIRSUPRA $587 16 payments
  3. ELIQUIS $536 32 payments
  4. BREZTRI $336 10 payments
  5. COLOGUARD DNA CAPTURE REAGENTS $211 14 payments
  6. TRELEGY ELLIPTA $166 9 payments
  7. CHANTIX $164 12 payments
  8. SYMBICORT $126 7 payments
  9. LEQVIO $104 4 payments
  10. ZEPBOUND $95 4 payments
  11. Other $1,581 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,932

Median for Internal Medicine: 777

Drug cost

$162,867

Median for Internal Medicine: $73,373

Branded share of claims

18.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $39,668
Mounjaro Tirzepatide Brand 22 $21,202
Farxiga Dapagliflozin Propanediol Brand 26 $20,572
Ozempic Semaglutide Brand 12 $13,509
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $13,220
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $11,430
Xarelto Rivaroxaban Brand 11 $10,657
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 178 $3,524
Albuterol Sulfate Hfa Albuterol Sulfate Brand 74 $2,800
Rosuvastatin Calcium Generic 33 $2,050

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$77,629

Medicare's payments for the services billed

Medicare patients

69

Average age 68

Services billed

1,123

34 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Depression 65%
COPD 48%
Diabetes 36%
Ischemic heart disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $249
$249 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $148
$148 26 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $29
$29 15 —
ELIQUIS
  • PFIZER INC. $16
$16 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record